• Algorae enters commercial & licensing agreement with Zydus Lifesciences Ltd
• Products intended for commercialisation in Australia and New Zealand
• Collaboration supports the parties' shared objective of expanding access to high quality medicines

Algorae Pharmaceuticals Ltd (ASX: 1AI) has entered into an exclusive commercial and licensing agreement for 10 products with Zydus Lifesciences Ltd (NSE: ZYDUSLIFE; BSE: 532321) for the Australian and New Zealand markets. The agreement establishes a framework under which the parties will collaborate on the introduction of a portfolio comprising injectable, oral and specialty pharmaceutical products across hospital and community care channels. The products are expected to be commercialised through Algorae's ANZ platform, subject to Therapeutic Goods Administration (TGA) and other applicable regulatory approvals. The collaboration strengthens Algorae's commercial platform and supports its objective of establishing a sustainable and compliant pharmaceutical supply presence in Australia and New Zealand. Zydus Lifesciences Ltd is a global pharmaceutical company with manufacturing and development capabilities spanning sterile injectables, oral dosage forms, specialty formulations and complex generics, supplying medicines into regulated and emerging markets worldwide.